Yue Xiang Yue Health | April 2026 Overview and Portfolio Highlights
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
INTVANEL
Developer of Energy Therapy Products and Urological Intervention Devices
Highlightll Pharma
Innovative Drug Developer
SMAVEW
SMAVEW
IASO Biotechnology
Cancer Treatment New Drug Developer
On April 28, a meeting of the Political Bureau of the CPC Central Committee was held to analyze the economic situation and deploy work. The meeting emphasized the precise and effective implementation of a more proactive fiscal policy and a moderately loose monetary policy to boost domestic demand and industrial upgrading, striving for a good start to the "15th Five-Year Plan."This sends a clear signal to the market: funds will flow primarily into science and technology innovation fields that align with national strategies, especially into "hard tech" sectors that can drive industrial upgrading.
As one of the earliest professional investment institutions in China to focus on the biomedicine and high-end medical device sectors, Everfront Capital has long adhered to the strategy of "investing early, investing small, and investing in hard technology," aligning with national strategies. This month, several companies invested in by Everfront Capital have reported significant progress in financing and business breakthroughs.
01
Progress of Portfolio Companies' IPOs and Financing
Nurelit
· NuriTech Completes Series E Financing, Radiopharmaceuticals Sector Welcomes Heavy Investment from "National Team"
Nurelit
· NuriTech Completes Series E Financing, Radiopharmaceuticals Sector Welcomes Heavy Investment from "National Team"
In April, Neurite announced the completion of an E-round financing exceeding 1 billion yuan. This is the largest financing event disclosed in China's nuclear medicine field so far this year.
Trinomab
· STAR MarketIPOPassed the review meeting of the Shanghai Stock Exchange Listing Review Committee
4Month3Day,TrinomabSTAR MarketIPOThe application has successfully passed the review of the Shanghai Stock Exchange Listing Review Committee.
Trinomab
· STAR MarketIPOPassed the review meeting of the Shanghai Stock Exchange Listing Review Committee
4Month3Day,TrinomabSTAR MarketIPOThe application has successfully passed the review of the Shanghai Stock Exchange Listing Review Committee.
Hyperdimensional Exploration
· Hyperdimensional Exploration N++ Completes Seed Round Financing
Hyperdimensional Exploration
· Hyperdimensional Exploration N++ Completes Seed Round Financing
Recently, Super Dimension Exploration announced the completion of a multi-million yuan seed round financing led by Edge Capital and Shenzhen Shiqin Investment.
INTVANEL
· Raised tens of millions in PRE-A+ fundingRound of Financing
Recently, INTVANEL completed a PRE-A+ round of financing worth tens of millions of yuan, led by EF Capital.
INTVANEL
· Raised tens of millions in PRE-A+ fundingRound of Financing
Recently, INTVANEL completed a PRE-A+ round of financing worth tens of millions of yuan, led by EF Capital.
Vbiosci
· Vbiosci Completes New Round of Multi-Million Financing
Vbiosci
· Vbiosci Completes New Round of Multi-Million Financing
Recently, VBiosci officially announced the completion of a new round of financing worth tens of millions of yuan, exclusively invested by EF Capital.
Recently, VBiosci officially announced the completion of a new round of financing worth tens of millions of yuan, exclusively invested by EF Capital.
02
Clinical and Commercial Dynamics of Invested Companies
GuangZhou GaoLing Pharmaceutical Company,Ltd.
· Blood-Brain Barrier Penetrating NLRP3 Inhibitor HL-400 Completes Phase I Clinical Trial in the United States
GuangZhou GaoLing Pharmaceutical Company,Ltd.
· Blood-Brain Barrier Penetrating NLRP3 Inhibitor HL-400 Completes Phase I Clinical Trial in the United States
On April 2, GaoGuang Pharmaceutical announced that its brain-penetrant NLRP3 inhibitor HL-400 has completed Phase I clinical trials in the United States.
· Ginocitib (TLL-018) Achieves Positive Topline Data in Phase III Clinical Trial for Rheumatoid Arthritis
Recently, GaoGuang Pharma announced that the Phase III clinical trial ("TARA Study") of its self-developed oral small molecule JAK1/TYK2 inhibitor Ginocitib for the treatment of active rheumatoid arthritis ("RA") has achieved positive topline results.
SMAVEW
· New Product Debut
SMAVEW
· New Product Debut
On April 10, SMAVEW made a stunning appearance at the exhibition with its multi-series representative products of light sheet microscopy imaging, and officially released the PilotView High-Content Intelligent Light Sheet Microscopy Imaging System.
IASO Bio
· International collaboration reached with Brazil's Butantan Institute to develop innovative therapies for hematological tumors
4Month10On [date], IASO Bio announced that itsWith Brazil's leading public institutionsButantanThe institute signed a technology cooperation and licensing agreement to develop treatments for hematological tumors in Brazil.CAR-TCell Therapy.
· CCTV 2CCTV Finance Visits IASO Bio Production Base
Recently,CCTV 2CCTV Finance Channel visits IASO Bio's production base located in Nanjing Biopharmaceutical Valley.
IASO Bio
· International collaboration reached with Brazil's Butantan Institute to develop innovative therapies for hematological tumors
4Month10On [date], IASO Bio announced that itsWith Brazil's leading public institutionsButantanThe institute signed a technology cooperation and licensing agreement to develop treatments for hematological tumors in Brazil.CAR-TCell Therapy.
· CCTV 2CCTV Finance Visits IASO Bio Production Base
Recently,CCTV 2CCTV Finance Channel visits IASO Bio's production base located in Nanjing Biopharmaceutical Valley.
Weimai Medical
· Interventional Robotics Industry's First Multi-Center Live Broadcast Redefines the Future of Interventional Surgery
Weimai Medical
· Interventional Robotics Industry's First Multi-Center Live Broadcast Redefines the Future of Interventional Surgery
Recently,CIT2026(The 24th Interventional Cardiology Congress of the Chinese Medical Association) has arrived as scheduled. Weiming Medical, in collaboration with the four top cardiovascular centers in China, has taken on the challenge.PCIThe Four Most Challenging High-Difficulty Lesions in the Field.
Recently,CIT2026(The 24th Interventional Cardiology Congress of the Chinese Medical Association) has arrived as scheduled. Weiming Medical, in collaboration with the four top cardiovascular centers in China, has taken on the challenge.PCIThe Four Most Challenging High-Difficulty Lesions in the Field.
Huamei Haolian
· Co-authored "AI Intelligent Agent Empowering Industry Decision-Making: Trends and Practices White Paper (2026)", case officially included.
On April 23-24, 2026, the "White Paper on AI Agents Empowering Industry Decision-Making: Trends and Practices (2026)" was officially released at the 2026 Academic Annual Conference of the Intelligence and Intelligent Cognition Special Committee. Huamei Haolian was invited to participate in the compilation, with Wu Lei, the company's AI R&D Director, joining the white paper drafting team as an expert; the "Dr. Hua AI Agent Empowering a Certain Insurance Institution Project" was listed as a typical practice case in the white paper.
Huamei Haolian
· Co-authored "AI Intelligent Agent Empowering Industry Decision-Making: Trends and Practices White Paper (2026)", case officially included.
On April 23-24, 2026, the "White Paper on AI Agents Empowering Industry Decision-Making: Trends and Practices (2026)" was officially released at the 2026 Academic Annual Conference of the Intelligence and Intelligent Cognition Special Committee. Huamei Haolian was invited to participate in the compilation, with Wu Lei, the company's AI R&D Director, joining the white paper drafting team as an expert; the "Dr. Hua AI Agent Empowering a Certain Insurance Institution Project" was listed as a typical practice case in the white paper.
Real Biotech
· Azvudine and Dohsitinib Combination Therapy Featured at AACR 2026
Real Biotech
· Azvudine and Dohsitinib Combination Therapy Featured at AACR 2026
Recently, the American Association for Cancer Research (AACR 2026) Annual Meeting Held in the U.S., Genuine Biotech Presented Preclinical Research Results of Azvudine and Dorisitinib Combination Therapy in Poster Format.
Recently, the American Association for Cancer Research (AACR 2026) Annual Meeting Held in the U.S., Genuine Biotech Presented Preclinical Research Results of Azvudine and Dorisitinib Combination Therapy in Poster Format.
Yingli Pharmaceutical
· Announcement of the First Patient Successfully Enrolled in the Phase II Clinical Trial of Novel HIPK2 Allosteric Inhibitor RLA-23174
Yingli Pharmaceutical
· Announcement of the First Patient Successfully Enrolled in the Phase II Clinical Trial of Novel HIPK2 Allosteric Inhibitor RLA-23174
Recently,Yingli PharmaceuticalAnnounced that it hasRila TherapeuticsJointly Developed Novel Small MoleculesHIPK2Allosteric InhibitorRLA-23174Tablet,ⅡThe first patient successfully enrolled in the Phase III clinical trial.
Recently,Yingli PharmaceuticalAnnounced that it hasRila TherapeuticsJointly Developed Novel Small MoleculesHIPK2Allosteric InhibitorRLA-23174Tablet,ⅡThe first patient successfully enrolled in the Phase III clinical trial.
Vbiosci
· Advancing Veterinary Epidemic Prevention into the Needle-Free Era
Vbiosci
· Advancing Veterinary Epidemic Prevention into the Needle-Free Era
Recently, the Porcine Epidemic Diarrhea Vaccine jointly applied for by Beijing Vbiosci Biotechnology Co., Ltd., its subsidiary Zhejiang Vbiosci Biological Products Co., Ltd., Jiangsu Academy of Agricultural Sciences, Veterinary Biological Products (Taizhou) Guotai Technology Innovation Center, and Jiangsu Leju Pharmaceutical Co., Ltd. was approved.Subunit Vaccine (293S32 Strain), successfully obtained the clinical trial approval issued by China's Ministry of Agriculture and Rural Affairs.
Recently, the Porcine Epidemic Diarrhea Vaccine jointly applied for by Beijing Vbiosci Biotechnology Co., Ltd., its subsidiary Zhejiang Vbiosci Biological Products Co., Ltd., Jiangsu Academy of Agricultural Sciences, Veterinary Biological Products (Taizhou) Guotai Technology Innovation Center, and Jiangsu Leju Pharmaceutical Co., Ltd. was approved.Subunit Vaccine (293S32 Strain), successfully obtained the clinical trial approval issued by China's Ministry of Agriculture and Rural Affairs.
SMAVEW Medical
· Setting Sail to Indonesia, Hand in Hand for Win-Win
SMAVEW Medical
· Setting Sail to Indonesia, Hand in Hand for Win-Win
Recently, the core team of Sinomax Medical traveled to Indonesia for business inspection and cooperation negotiations. Focusing on electronic injection pens and digital medication management solutions, they reached in-depth cooperation consensus with Indonesia's national health insurance institutions, local medical systems, and authoritative social organizations.
Recently, the core team of Sinomax Medical traveled to Indonesia for business inspection and cooperation negotiations. Focusing on electronic injection pens and digital medication management solutions, they reached in-depth cooperation consensus with Indonesia's national health insurance institutions, local medical systems, and authoritative social organizations.
Kaituo Bio
· RNA-LNP Lyophilization Production Line Officially Launched, Accelerating the Upgrade of Next-Generation RNA Drug Delivery
Kaituo Bio
· RNA-LNP Lyophilization Production Line Officially Launched, Accelerating the Upgrade of Next-Generation RNA Drug Delivery
4Month，Kaituo BioRNA-LNPFreeze-dried production line officially begins operation, further enhancing the company's capabilities in China.RNAFull-chain service capabilities in the field of pharmaceutical formulations.
4Month，Kaituo BioRNA-LNPFreeze-dried production line officially begins operation, further enhancing the company's capabilities in China.RNAFull-chain service capabilities in the field of pharmaceutical formulations.
West Lake Omics
· Unveiling the "AI + Spatiotemporal" Hardcore Matrix at CCTB
West Lake Omics
· Unveiling the "AI + Spatiotemporal" Hardcore Matrix at CCTB
4Month24Day-26Day,Chinese Tumor Biomarkers Academic Conference & Integrated Oncology Academic Conference & Young Scientists Conference on Tumor Biomarkers & Tumor Biomarkers Industry Innovation Conference (CCTBThe conference was held in Chengdu, with Westlake Omics bringing "AI+"Space-Time" Hardcore Matrix Debuts。
4Month24Day-26Day,Chinese Tumor Biomarkers Academic Conference & Integrated Oncology Academic Conference & Young Scientists Conference on Tumor Biomarkers & Tumor Biomarkers Industry Innovation Conference (CCTBThe conference was held in Chengdu, with Westlake Omics bringing "AI+"Space-Time" Hardcore Matrix Debuts。
Century KONTAI
· All-Around Hydrophobic Preloaded Intraocular Lens ASOB55LPS Successfully Added to National Procurement
Century KONTAI
· All-Around Hydrophobic Preloaded Intraocular Lens ASOB55LPS Successfully Added to National Procurement
4Month16On [date], the Joint Procurement Office for High-Value Medical Consumables of the National Organization officially released the "Announcement on Supplementary Products for Centralized Bulk Procurement of Artificial Crystals and Sports Medicine Related Medical Consumables," Century Kangtai.Independently developed brand-new generation all-purpose hydrophobic intraocular lens (Model:ASOB55LPS) successfully included in the national centralized bulk procurement directory.
4Month16On [date], the Joint Procurement Office for High-Value Medical Consumables of the National Organization officially released the "Announcement on Supplementary Products for Centralized Bulk Procurement of Artificial Crystals and Sports Medicine Related Medical Consumables," Century Kangtai.Independently developed brand-new generation all-purpose hydrophobic intraocular lens (Model:ASOB55LPS) successfully included in the national centralized bulk procurement directory.
· Multiple Hospitals Complete the Implantation of VisionAid
Recently, Quanzhou Aier Eye Hospital's Business Dean and Tianjin Medical University General Hospital successfully completed the implantation of VisionMax® Ultra-EDoF.
Huahao Zhongtian
· Four Clinical Research Achievements of Utidelone Unveiled Simultaneously
Huahao Zhongtian
· Four Clinical Research Achievements of Utidelone Unveiled Simultaneously
03
Approval Status of New Drugs and Devices from Invested Companies
SUNSE BIO
· FRSW117 Ultra-Long-Acting Recombinant Factor VIII Marketing Application Accepted by NMPA
SUNSE BIO
· FRSW117 Ultra-Long-Acting Recombinant Factor VIII Marketing Application Accepted by NMPA
On April 29, Shengsi Bio announced that its Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (Project Code: FRSW117) has submitted a marketing application to the National Medical Products Administration (NMPA) and has been officially accepted.
On April 29, Shengsi Bio announced that its Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (Project Code: FRSW117) has submitted a marketing application to the National Medical Products Administration (NMPA) and has been officially accepted.
CircCode Bio
· HM2003 Granted FDA "Fast Track" Designation
CircCode Bio
· HM2003 Granted FDA "Fast Track" Designation
On April 13, Huanma Biotech announced that its core circular RNA technology...New Drug HM2003 Injection Successfully Granted FDA Fast Track Designation in the United States.
On April 13, Huanma Biotech announced that its core circular RNA technology...New Drug HM2003 Injection Successfully Granted FDA Fast Track Designation in the United States.
Tianqin Bio
· 助力滨会生物mRNA新药获美国FDA临床批件
Tianqin Bio
· 助力滨会生物mRNA新药获美国FDA临床批件
Recently,BinHui BioIndependently DevelopedLNPDeliveryIL-2AnalogsmRNACandidate DrugBR003Obtained approval from the U.S. Food and Drug Administration (FDA) Clinical Trial Permit (IND), TQ Biotech Wuhan Branch has undertakenBR003Non-clinical toxicology and pharmacokinetic studies.
04
Honors of Invested Enterprises
Included in the CDE "Starlight Program"
· Ascentage Pharma MDM2-p53 Inhibitor APG-115
Included in the CDE "Starlight Program"
· Ascentage Pharma MDM2-p53 Inhibitor APG-115
Awarded InvestmentChina's 2025 Medical and Health Services Industry
Top 5 Investment Cases in the Best Medical Service Field
Awarded InvestmentChina's 2025 Medical and Health Services Industry
Top 5 Investment Cases in the Best Medical Service Field
· Huamei Haolian
· Huamei Haolian
Awarded InvestmentChina's 2025 Medical and Health Services Industry
Top 10 Best Investment Cases in the Medical Device Field
· Core Medical、Nurotron
Awarded InvestmentChina's 2025 Medical and Health Services Industry
Top 10 Best Investment Cases in the Medical Device Field
· Core Medical、Nurotron
EntrySelectThe 10th Everything Growth Conference-2026Future Unicorn Enterprises in ChinaTOP100&Hangzhou Unicorn-Breed Enterprises List
· LingSMAVEW
EntrySelectThe 10th Everything Growth Conference-2026Future Unicorn Enterprises in ChinaTOP100&Hangzhou Unicorn-Breed Enterprises List
· LingSMAVEW
RongNo FutureWorry2026Outstanding Employer Certification
· Trinomab
RongNo FutureWorry2026Outstanding Employer Certification
· Trinomab
Awarded by Wuhan Economic and Information Technology Bureau"Recognition of Industrial Enterprises above Designated Size"
· SMAVEW
Awarded by Wuhan Economic and Information Technology Bureau"Recognition of Industrial Enterprises above Designated Size"
· SMAVEW
Re-ascend to the Myriad Things Growth Conference"Hangzhou Near-Unicorn Enterprises" List
Awarded2025 Annual Hangzhou "New Eaglets" Enterprises
· West Lake Omics
Re-ascend to the Myriad Things Growth Conference"Hangzhou Near-Unicorn Enterprises" List
Awarded2025 Annual Hangzhou "New Eaglets" Enterprises
· West Lake Omics
Honored High MedicalExpand [2026 【Breakthrough Innovation Award for High-End Medical Devices】
· Zifu Medical Capsule Endoscopy System
Honored High MedicalExpand [2026 【Breakthrough Innovation Award for High-End Medical Devices】
· Zifu Medical Capsule Endoscopy System
05
Yifeng Honor
▷Hit
Yifeng Capital-
Top 50 Best Chinese Venture Capital Institutions in China for 2025
Top 20 Investment Institutions in the Medical Device Sector of China's Healthcare and Health Services Industry for 2025
Top 100 Best Venture Capital Institutions in China for 2025
Yifeng Capital CEO Zhu Pai-
2025 Nova Rising Star Investor
▷ Mother Fund Research Center
Yifeng Capital CEO Zhu Pai-
2026 40 Under 40 (40U40) Best Direct Investment Fund Young Investors
05
Yifeng Honor
▷Hit
Yifeng Capital-
Top 50 Best Chinese Venture Capital Institutions in China for 2025
Top 20 Investment Institutions in the Medical Device Sector of China's Healthcare and Health Services Industry for 2025
Top 100 Best Venture Capital Institutions in China for 2025
Yifeng Capital CEO Zhu Pai-
2025 Nova Rising Star Investor
▷ Mother Fund Research Center
Yifeng Capital CEO Zhu Pai-
2026 40 Under 40 (40U40) Best Direct Investment Fund Young Investors